JP2013517781A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013517781A5 JP2013517781A5 JP2012550437A JP2012550437A JP2013517781A5 JP 2013517781 A5 JP2013517781 A5 JP 2013517781A5 JP 2012550437 A JP2012550437 A JP 2012550437A JP 2012550437 A JP2012550437 A JP 2012550437A JP 2013517781 A5 JP2013517781 A5 JP 2013517781A5
- Authority
- JP
- Japan
- Prior art keywords
- fgf23
- composition
- sequence
- seq
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100024802 Fibroblast growth factor 23 Human genes 0.000 claims 22
- 101001051973 Homo sapiens Fibroblast growth factor 23 Proteins 0.000 claims 22
- 229920001184 polypeptide Polymers 0.000 claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 230000035772 mutation Effects 0.000 claims 15
- 239000012634 fragment Substances 0.000 claims 11
- 150000001413 amino acids Chemical class 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000009490 IgG Receptors Human genes 0.000 claims 2
- 108010073807 IgG Receptors Proteins 0.000 claims 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 2
- 101100444898 Mus musculus Egr1 gene Proteins 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 108091008794 FGF receptors Proteins 0.000 claims 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims 1
- 101001139093 Homo sapiens Klotho Proteins 0.000 claims 1
- 102100020686 Klotho Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000000865 phosphorylative effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/696,693 US8420088B2 (en) | 2008-01-28 | 2010-01-29 | Methods and compositions using FGF23 fusion polypeptides |
| US12/696,693 | 2010-01-29 | ||
| PCT/EP2011/051112 WO2011092234A1 (en) | 2010-01-29 | 2011-01-27 | Methods and compositions using fgf23 fusion polypeptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016087432A Division JP2016190847A (ja) | 2010-01-29 | 2016-04-25 | Ｆｇｆ２３融合ポリペプチドを使用する方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013517781A JP2013517781A (ja) | 2013-05-20 |
| JP2013517781A5 true JP2013517781A5 (cg-RX-API-DMAC7.html) | 2014-01-16 |
| JP5964243B2 JP5964243B2 (ja) | 2016-08-03 |
Family
ID=43828141
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012550437A Expired - Fee Related JP5964243B2 (ja) | 2010-01-29 | 2011-01-27 | Ｆｇｆ２３融合ポリペプチドを使用する方法および組成物 |
| JP2016087432A Pending JP2016190847A (ja) | 2010-01-29 | 2016-04-25 | Ｆｇｆ２３融合ポリペプチドを使用する方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016087432A Pending JP2016190847A (ja) | 2010-01-29 | 2016-04-25 | Ｆｇｆ２３融合ポリペプチドを使用する方法および組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8420088B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2529016B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5964243B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20130032296A (cg-RX-API-DMAC7.html) |
| CN (3) | CN105968208A (cg-RX-API-DMAC7.html) |
| AR (1) | AR080043A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011209380B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2787285A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201201047A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2605302T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX336391B (cg-RX-API-DMAC7.html) |
| PL (1) | PL2529016T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2529016T (cg-RX-API-DMAC7.html) |
| TW (2) | TWI430805B (cg-RX-API-DMAC7.html) |
| UY (1) | UY33204A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011092234A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8420088B2 (en) | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
| TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| US8951966B2 (en) | 2011-07-01 | 2015-02-10 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| WO2014085365A2 (en) | 2012-11-28 | 2014-06-05 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| CN102961739A (zh) * | 2012-12-12 | 2013-03-13 | 黄曙 | Klotho蛋白的用途 |
| DK2938740T3 (da) | 2012-12-27 | 2022-06-20 | Ngm Biopharmaceuticals Inc | Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2014152993A1 (en) * | 2013-03-14 | 2014-09-25 | The Board Of Regents Of The University Of Oklahoma | Use of klotho nucleic acids or proteins for treatment of diabetes and diabetes-related conditions |
| KR101492710B1 (ko) * | 2013-04-03 | 2015-02-13 | 중앙대학교 산학협력단 | Fgf23 유전자를 이용한 전립선암 진단용 마커 및 이를 이용한 전립선암 예측 및 진단 방법 |
| ES2714127T3 (es) | 2013-10-24 | 2019-05-27 | Tokyo Metropolitan Geriatric Hospital And Inst Of Gerontology | Células madre musculares o mioblastos, procedimiento de cribado de sustancias que participan en la conversión metabólica usando las mismas, y composición farmacéutica que comprende la sustancia obtenida de dicho procedimiento del cribado |
| WO2015065897A1 (en) | 2013-10-28 | 2015-05-07 | Ngm Biopharmaceuticals, Inc. | Cancer models and associated methods |
| US20150140036A1 (en) | 2013-11-13 | 2015-05-21 | Novartis Institutes For Biomedical Research, Inc. | Low, immune enhancing, dose mtor inhibitors and uses thereof |
| CN106662577B (zh) | 2014-01-24 | 2020-07-21 | 恩格姆生物制药公司 | 结合蛋白及其使用方法 |
| JP6370577B2 (ja) * | 2014-03-26 | 2018-08-08 | 国立大学法人京都工芸繊維大学 | 抗老化物質のスクリーニング方法 |
| WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
| WO2015195509A2 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| WO2016065106A1 (en) | 2014-10-23 | 2016-04-28 | Ngm Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| US10654909B2 (en) * | 2014-12-04 | 2020-05-19 | Novartis Ag | Soluble alpha klotho and serum albumin fusion protein |
| US10632180B2 (en) | 2015-02-06 | 2020-04-28 | The Regents Of The University Of California | Methods and compositions for improved cognition |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| WO2017083276A1 (en) | 2015-11-09 | 2017-05-18 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| CN116478907A (zh) * | 2016-06-02 | 2023-07-25 | 克洛索治疗有限公司 | 治疗性重组klotho蛋白及其组合物和方法 |
| EA037848B1 (ru) * | 2016-07-14 | 2021-05-27 | Общество С Ограниченной Ответственностью "Биохимический Агент" | Гибридный белок, полинуклеотид, генетическая конструкция, продуцент, препарат для регенерации хряща (варианты) |
| US11123438B2 (en) | 2016-08-19 | 2021-09-21 | Ampsource Biopharma Shanghai Inc. | Linker peptide for constructing fusion protein |
| CN107759696A (zh) | 2016-08-19 | 2018-03-06 | 安源医药科技（上海）有限公司 | 人白介素7融合蛋白及其制备方法 |
| CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| CA3034399A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| CN113692411A (zh) * | 2019-04-19 | 2021-11-23 | 吉尼松公司 | 成纤维细胞生长因子23相关的低磷酸盐血症的基因治疗 |
| WO2021128065A1 (zh) * | 2019-12-25 | 2021-07-01 | 广州菲康生物技术有限公司 | 人fgf-23的荧光免疫层析试纸和人fgf-23的荧光免疫层析检测试剂盒 |
| US11028132B1 (en) | 2020-04-07 | 2021-06-08 | Yitzhak Rosen | Half-life optimized linker composition |
| US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
| US20250154487A1 (en) * | 2023-11-10 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Engineered alpha klotho polypeptides and uses thereof |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL71691A (en) | 1984-04-27 | 1991-04-15 | Yeda Res & Dev | Production of interferon-ypsilon |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US5266561A (en) | 1988-01-11 | 1993-11-30 | Amylin Pharmaceuticals, Inc. | Treatment of type 2 diabetes mellitus |
| CA2071867A1 (en) | 1989-11-06 | 1991-05-07 | Edith Mathiowitz | Method for producing protein microspheres |
| AU646877B2 (en) | 1990-06-15 | 1994-03-10 | Scios Nova Inc. | Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease |
| US5408038A (en) * | 1991-10-09 | 1995-04-18 | The Scripps Research Institute | Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US5420112A (en) | 1992-06-12 | 1995-05-30 | Lewis; Michael E. | Prevention and treatment of peripheral neuropathy |
| US5541094A (en) * | 1992-09-25 | 1996-07-30 | E. I. Du Pont De Nemours And Company | Glyoxylic acid/aminomethylphosphonic acid mixtures prepared using a microbial transformant |
| US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| US6187992B1 (en) | 1994-12-05 | 2001-02-13 | Merck & Co., Inc. | Transgenic mouse having a disrupted amyloid precursor protein gene |
| US5916597A (en) | 1995-08-31 | 1999-06-29 | Alkermes Controlled Therapeutics, Inc. | Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent |
| US6194177B1 (en) | 1996-02-20 | 2001-02-27 | Applied Research Systems Ars Holding N.V. | DNA encoding a hybrid heterodimeric protein |
| CA2244253C (en) | 1996-03-15 | 2002-11-12 | Somerset Pharmaceuticals, Inc. | Method for preventing and treating peripheral neuropathy by administering selegiline |
| US6358752B1 (en) | 1996-09-27 | 2002-03-19 | Cornell Research Foundation, Inc. | Liposome-enhanced test device and method |
| KR20000062345A (ko) | 1996-12-26 | 2000-10-25 | 히라타 다다시 | 신규 폴리펩타이드, 신규 ｄｎａ 및 신규 항체 |
| US6127598A (en) | 1997-07-25 | 2000-10-03 | The Regents Of The University Of California | NKX-2.2 and NKX-6.1 transgenic mouse models for diabetes, depression, and obesity |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| CA2323638A1 (en) | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
| US7060479B2 (en) * | 1999-12-08 | 2006-06-13 | Serono Genetics Institute, S.A. | Full-length human cDNAs encoding potentially secreted proteins |
| US20030055231A1 (en) | 1998-10-28 | 2003-03-20 | Jian Ni | 12 human secreted proteins |
| DE60026287T2 (de) | 1999-04-22 | 2006-08-17 | Liposcience, Inc. | Nmr-verfahren zur bestimmung des risikos zur entwicklung von diabetes type 2 |
| EP1200629B1 (en) | 1999-08-12 | 2008-01-16 | Wisconsin Alumni Research Foundation | Identification of genetic markers of biological age and metabolism |
| US6569832B1 (en) | 1999-11-12 | 2003-05-27 | Novo Nordisk A/S | Inhibition of beta cell degeneration |
| US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
| US6406853B1 (en) | 1999-12-23 | 2002-06-18 | The Regents Of The University Of California | Interventions to mimic the effects of calorie restriction |
| JP2006238894A (ja) * | 2000-02-15 | 2006-09-14 | Amgen Inc | 線維芽細胞成長因子−２３分子およびその使用 |
| US20060160181A1 (en) * | 2000-02-15 | 2006-07-20 | Amgen Inc. | Fibroblast Growth Factor-23 molecules and uses thereof |
| EP1261638A2 (en) | 2000-03-08 | 2002-12-04 | Chiron Corporation | Human fgf-23 gene and gene expression products |
| JP2004504063A (ja) | 2000-07-19 | 2004-02-12 | アドバンスド リサーチ ＆ テクノロジー インスティテュート | 新規線維芽細胞増殖因子（ｆｇｆ２３）および使用方法 |
| EP1425289A4 (en) | 2001-01-30 | 2004-10-13 | Regeneron Pharma | NOVEL NUCLEIC ACID AND POLYPEPTIDE MOLECULES |
| US7588757B2 (en) | 2001-03-14 | 2009-09-15 | Genzyme Corporation | Methods of treating Parkinson's disease using recombinant adeno-associated virus virions |
| US20040171825A1 (en) * | 2001-04-26 | 2004-09-02 | Lydie Bougueleret | Human fibroblast growth factor-related compositions |
| EP1327443A1 (en) | 2001-12-21 | 2003-07-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic or preventing agent for the diseases caused by a decrease in the expression level of the klotho protein |
| US7217798B2 (en) | 2003-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of Fc-fusion protein serum half-lives by mutagenesis |
| US20050004348A1 (en) * | 2002-12-23 | 2005-01-06 | Miyamoto Ken-Ichi | Novel type II Na/Pi cotransporters and type II Na/Pi cotransporter expression regulatory factors |
| TW200936156A (en) * | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| US8420088B2 (en) | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
| US20110015345A1 (en) * | 2008-03-19 | 2011-01-20 | Ambrx, Inc. | Modified FGF-23 Polypeptides and Their Uses |
| SG195542A1 (en) | 2008-10-10 | 2013-12-30 | Amgen Inc | Fgf21 mutants and uses thereof |
| JP2012525847A (ja) | 2009-05-05 | 2012-10-25 | アムジエン・インコーポレーテツド | Ｆｇｆ２１変異体およびその使用 |
| US8461111B2 (en) | 2009-05-20 | 2013-06-11 | Florida State University Research Foundation | Fibroblast growth factor mutants having improved functional half-life and methods of their use |
| US20110195077A1 (en) | 2010-01-29 | 2011-08-11 | Novartis Ag | Methods and compositions using fgf23 fusion ppolypeptides |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
-
2010
- 2010-01-29 US US12/696,693 patent/US8420088B2/en not_active Expired - Fee Related
-
2011
- 2011-01-27 MX MX2012008780A patent/MX336391B/es unknown
- 2011-01-27 CN CN201610245160.1A patent/CN105968208A/zh not_active Withdrawn
- 2011-01-27 WO PCT/EP2011/051112 patent/WO2011092234A1/en not_active Ceased
- 2011-01-27 EP EP11705830.5A patent/EP2529016B1/en active Active
- 2011-01-27 JP JP2012550437A patent/JP5964243B2/ja not_active Expired - Fee Related
- 2011-01-27 CN CN201180007622.1A patent/CN102725413B/zh active Active
- 2011-01-27 ES ES11705830.5T patent/ES2605302T3/es active Active
- 2011-01-27 PT PT117058305T patent/PT2529016T/pt unknown
- 2011-01-27 KR KR1020127022498A patent/KR20130032296A/ko not_active Withdrawn
- 2011-01-27 EA EA201201047A patent/EA201201047A1/ru unknown
- 2011-01-27 AU AU2011209380A patent/AU2011209380B2/en not_active Ceased
- 2011-01-27 PL PL11705830T patent/PL2529016T3/pl unknown
- 2011-01-27 AR ARP110100273A patent/AR080043A1/es unknown
- 2011-01-27 CN CN201310049110.2A patent/CN103204941B/zh active Active
- 2011-01-27 UY UY0001033204A patent/UY33204A/es not_active Application Discontinuation
- 2011-01-27 EP EP16184724.9A patent/EP3124612A1/en not_active Withdrawn
- 2011-01-27 CA CA2787285A patent/CA2787285A1/en not_active Withdrawn
- 2011-01-28 TW TW100103508A patent/TWI430805B/zh active
- 2011-01-28 TW TW103100421A patent/TWI569805B/zh not_active IP Right Cessation
-
2013
- 2013-03-12 US US13/796,711 patent/US8932589B2/en not_active Expired - Fee Related
-
2014
- 2014-11-03 US US14/531,620 patent/US9475857B2/en active Active
-
2016
- 2016-04-25 JP JP2016087432A patent/JP2016190847A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013517781A5 (cg-RX-API-DMAC7.html) | ||
| Yamazaki et al. | Snake venom Vascular Endothelial Growth Factors (VEGF-Fs) exclusively vary their structures and functions among species | |
| JP2022043042A5 (cg-RX-API-DMAC7.html) | ||
| TW201129373A (en) | Methods and compositions using FGF23 fusion polypeptides | |
| Reeks et al. | Privileged frameworks from snake venom | |
| JP2017018125A5 (cg-RX-API-DMAC7.html) | ||
| KR102483242B1 (ko) | Mg53 돌연변이체, 및 그의 제조 방법 및 그의 용도 | |
| JP2010534486A5 (cg-RX-API-DMAC7.html) | ||
| WO2008038287A3 (en) | N-terminal fgf variants having increased receptor selectivity and uses thereof | |
| JP2015532654A5 (cg-RX-API-DMAC7.html) | ||
| JP2017500035A5 (cg-RX-API-DMAC7.html) | ||
| JP2013537400A5 (cg-RX-API-DMAC7.html) | ||
| JP2017140032A (ja) | 線維芽細胞増殖因子の熱安定性変異体 | |
| WO2008022759A3 (en) | Specific and high affinity binding proteins comprising modified sh3 domains of fyn kinase | |
| JP2010529860A5 (cg-RX-API-DMAC7.html) | ||
| CN105246503A (zh) | Pcsk9的新颖结合蛋白 | |
| Fujisawa et al. | Catalytically inactive phospholipase A2 homologue binds to vascular endothelial growth factor receptor-2 via a C-terminal loop region | |
| Gasparian et al. | Overexpression in Escherichia coli and purification of human fibroblast growth factor (FGF-2) | |
| JP2016503434A5 (cg-RX-API-DMAC7.html) | ||
| JP2008521795A5 (cg-RX-API-DMAC7.html) | ||
| US11746134B2 (en) | Human FGF21 mutant with improved effectiveness and stability and pharmaceutical composition thereof | |
| CN116075524A (zh) | 转铁蛋白受体结合蛋白 | |
| JPWO2020160514A5 (cg-RX-API-DMAC7.html) | ||
| Campion et al. | Cumulative effect of double-site mutations of human epidermal growth factor on receptor binding. | |
| Liao et al. | Identification of two amino acids within the EIIIA (ED-A) segment of fibronectin constituting the epitope for two function-blocking monoclonal antibodies |